Arcturus Therapeutics Holdings Inc. (NasdaqGM: ARCT)
Health Care · Biotechnology · US
$12.61
-8.22% today · -29.1% 1Y
Arcturus Therapeutics Holdings Inc. (NasdaqGM: ARCT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $390.53M and employs 109 people.
Over the last twelve months the share price has lost 29.1%, trading between 5.50 and 24.17.
Tweenvest scores Arcturus Therapeutics Holdings Inc. across four factors: quality 47/100, value 33/100, growth 0/100. Its strongest factor is quality.
ARCT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $390.53M
- Revenue (TTM)
- $29.37M
- P/E
- —
- EPS
- -3.33
- Dividend yield
- —
- Beta (5Y)
- 2.48
- 52-week high
- $24.17
- 52-week low
- $5.50
- Avg volume (3M)
- —
- Shares outstanding
- 28.42M
- Employees
- 109
- Next earnings
- —
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
- ISIN
- US03969T1097
- Founded
- 2013
- Listed since
- May 22, 2013
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Prelude Therapeutics IncorporatedNasdaqGS: PRLD | $400.65M | $3.74 | -3.86% |
| Laekna, Inc.SEHK: 2105 | $400.21M | HK$7.37 | -15.77% |
| Galectin Therapeutics Inc.NasdaqCM: GALT | $397.35M | $3.87 | -1.78% |
| Eikon Therapeutics, Inc.NasdaqGS: EIKN | $393.24M | $7.26 | -2.81% |
| vTv Therapeutics Inc.NasdaqCM: VTVT | $387.40M | $30.46 | -2.31% |
| Opus Genetics, Inc.NasdaqCM: IRD | $386.03M | $4.64 | -0.22% |
| Formycon AGXTRA: FYB | $384.18M | €19.46 | +2.10% |
| Kyverna Therapeutics, Inc.NasdaqGS: KYTX | $384.05M | $6.21 | -2.82% |
Figures last refreshed Oct 11, 2026.